BioStem Technologies, Inc. (BSEM)
USD 16.5
(-2.94%)
USD 16.5
(-2.94%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 4.71 Million USD | -6.19% |
| 2022 | 5.08 Million USD | 5.34% |
| 2021 | 4.83 Million USD | -14.11% |
| 2020 | 5.62 Million USD | 9.98% |
| 2019 | 5.11 Million USD | -1.65% |
| 2018 | 5.2 Million USD | 444.55% |
| 2017 | 955 Thousand USD | 6.11% |
| 2016 | 900 Thousand USD | 80.0% |
| 2015 | 500 Thousand USD | 150.37% |
| 2014 | 199.7 Thousand USD | 405.46% |
| 2013 | 39.5 Thousand USD | -42.32% |
| 2012 | 68.5 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 4.22 Million USD | 4.62% |
| 2024 Q1 | 4.35 Million USD | -8.68% |
| 2023 Q2 | 5.81 Million USD | 15.84% |
| 2023 Q3 | 6.02 Million USD | 3.65% |
| 2023 FY | 4.77 Million USD | -6.19% |
| 2023 Q4 | 4.77 Million USD | -20.75% |
| 2023 Q1 | 5.01 Million USD | -1.42% |
| 2022 Q3 | 4.98 Million USD | -1.09% |
| 2022 FY | 5.08 Million USD | 5.34% |
| 2022 Q4 | 5.08 Million USD | 2.14% |
| 2022 Q1 | 4.89 Million USD | 1.39% |
| 2022 Q2 | 5.03 Million USD | 2.83% |
| 2021 Q3 | 5.48 Million USD | -4.91% |
| 2021 FY | 4.83 Million USD | -14.11% |
| 2021 Q4 | 4.83 Million USD | -11.89% |
| 2021 Q1 | 5.78 Million USD | 2.81% |
| 2021 Q2 | 5.76 Million USD | -0.29% |
| 2020 Q3 | 5.64 Million USD | -0.31% |
| 2020 Q1 | 5.13 Million USD | 0.33% |
| 2020 Q4 | 5.62 Million USD | -0.29% |
| 2020 FY | 5.62 Million USD | 9.98% |
| 2020 Q2 | 5.65 Million USD | 10.28% |
| 2019 FY | 5.11 Million USD | -1.65% |
| 2019 Q4 | 5.11 Million USD | 0.0% |
| 2018 Q1 | 1.04 Million USD | 4.01% |
| 2018 FY | 5.2 Million USD | 444.55% |
| 2018 Q2 | 1.61 Million USD | 54.81% |
| 2017 Q1 | 980 Thousand USD | 8.89% |
| 2017 Q3 | 935 Thousand USD | -10.1% |
| 2017 Q4 | 1 Million USD | 6.95% |
| 2017 FY | 955 Thousand USD | 6.11% |
| 2017 Q2 | 1.04 Million USD | 6.12% |
| 2016 Q1 | 500 Thousand USD | 0.0% |
| 2016 Q4 | 900 Thousand USD | 0.0% |
| 2016 FY | 900 Thousand USD | 80.0% |
| 2016 Q2 | 540 Thousand USD | 8.0% |
| 2016 Q3 | 900 Thousand USD | 66.67% |
| 2015 Q1 | 12.62 Thousand USD | -93.68% |
| 2015 Q2 | 15.32 Thousand USD | 21.38% |
| 2015 Q4 | 500 Thousand USD | 2635.83% |
| 2015 Q3 | 18.27 Thousand USD | 19.27% |
| 2015 FY | 500 Thousand USD | 150.37% |
| 2014 Q4 | 199.7 Thousand USD | 383.15% |
| 2014 Q1 | 36.5 Thousand USD | -7.59% |
| 2014 Q2 | 24.5 Thousand USD | -32.87% |
| 2014 Q3 | 41.33 Thousand USD | 68.65% |
| 2014 FY | 199.7 Thousand USD | 405.46% |
| 2013 Q1 | 68.5 Thousand USD | 0.0% |
| 2013 Q2 | 102.65 Thousand USD | 49.85% |
| 2013 Q3 | 60 Thousand USD | -41.54% |
| 2013 Q4 | 39.5 Thousand USD | -34.16% |
| 2013 FY | 39.5 Thousand USD | -42.32% |
| 2012 FY | 68.5 Thousand USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 88.565% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -14.3% |
| SQZ Biotechnologies Company | 27.47 Million USD | 82.849% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 89.137% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 84.172% |
| Mesoblast Limited | 118.7 Million USD | 96.031% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -396.843% |
| Genus plc | 233.1 Million USD | 97.979% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -60.778% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -250.66% |
| Marizyme, Inc. | 18.71 Million USD | 74.829% |
| ContraFect Corporation | 2.88 Million USD | -63.534% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -528.189% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -3377.394% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -225.752% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -102.558% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 16.735% |
| MultiCell Technologies, Inc. | 202.58 USD | -2325606.881% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 91.805% |
| EV Biologics, Inc. | 1.49 Million USD | -215.197% |
| Q BioMed Inc. | 4.1 Million USD | -14.634% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 85.767% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -647.753% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -283.553% |
| Biomind Labs Inc. | 735.54 Thousand USD | -540.537% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 97.254% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 63.75% |
| Skye Bioscience, Inc. | 4.61 Million USD | -2.083% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -430.527% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -3229.2% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 19.752% |
| IMV Inc. | 28.88 Million USD | 83.688% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -18218.819% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -108.619% |
| GB Sciences, Inc. | 1.75 Million USD | -167.8% |
| Alpha Cognition Inc. | 1.22 Million USD | -286.064% |
| HST Global, Inc. | 98.31 Thousand USD | -4691.97% |
| CSL Limited | 12.18 Billion USD | 99.961% |
| Halberd Corporation | 150 Thousand USD | -3040.945% |
| Enzolytics Inc. | 996.33 Thousand USD | -372.873% |
| Resverlogix Corp. | 6.49 Million USD | 27.416% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -886.684% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -1743.335% |
| argenx SE | 20 Million USD | 76.443% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 89.659% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -73.936% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -45977.428% |
| Genscript Biotech Corporation | 417.73 Million USD | 98.872% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -2248.475% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -96.495% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -1954.776% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 93.035% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -55.688% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1209.782% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 76.823% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -3069.385% |
| ONE Bio Corp. | 19.71 Million USD | 76.102% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -1783.196% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -1794.265% |
| Agentix Corp. | 50 Thousand USD | -9322.834% |
| LadRx Corporation | 33.6 Thousand USD | -13919.571% |
| Cell Source, Inc. | 9.25 Million USD | 49.089% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -523.035% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -523.035% |
| NovAccess Global Inc. | 2.19 Million USD | -114.167% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 33.387% |
| Itoco Inc. | 228.37 Thousand USD | -1963.0% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -2133.164% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 5.45% |
| Kadimastem Ltd | 891.22 Thousand USD | -428.644% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1072.435% |
| CytoDyn Inc. | 30.07 Million USD | 84.335% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -872.862% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -1239.053% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 39.751% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -3746.055% |
| Rebus Holdings, Inc. | 310 Thousand USD | -1419.812% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 0.504% |
| International Stem Cell Corporation | 4.17 Million USD | -12.767% |
| Bioxytran, Inc. | 1.92 Million USD | -144.749% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -7448.775% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -116.031% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 43.345% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 45.12% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -202.892% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -1657.991% |
| Neutra Corp. | 54.15 Thousand USD | -8599.714% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -157.454% |
| PureTech Health plc | 25.51 Million USD | 81.533% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -284.849% |
| IXICO plc | 472.02 Thousand USD | -898.133% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 69.606% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 92.433% |
| CSL Limited | 12.18 Billion USD | 99.961% |
| Cellectis S.A. | 92.77 Million USD | 94.922% |